Leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000587
English
Authors' recommendations:
Leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS) is recommended as an option for use within NHS Wales as neoadjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2419
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Aged
- Aged, 80 and over
- Asian People
- Drug Administration Schedule
- Male
- Middle Aged
- Treatment Outcome
- Antineoplastic Agents, Hormonal
- Hot Flashes
- Leuprolide
- Penis
- Prostate-Specific Antigen
- Prostatic Neoplasms
- Testis
- Testosterone
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.